This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hayes, V. M. Articles by Sutherland, R. L. Search for Related Content PubMed PubMed Citation Articles by Hayes, V. M. Articles by Sutherland, R. L.

Macrophage Inhibitory Cytokine-1 H6D Polymorphism, Prostate Cancer Risk, and Survival

¹ Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia; ² University of New South Wales, Sydney, New South Wales, Australia; ³ Cancer Epidemiology Centre, The Cancer Council Victoria; ⁴ Department of Pathology and ⁵ Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Carlton, Victoria, Australia; and ⁶ IARC, Lyon, France

Requests for reprints: Vanessa M. Hayes, Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales 2010, Australia. Phone: 61-2-92958345; Fax: 61-2-92958321. E-mail: v.hayes{at}garvan.org.au

Macrophage inhibitory cytokine-1 (MIC-1), a member of the transforming growth factor-ß superfamily, is important in regulating inflammation. Inflammation of the prostate has been suggested to favor tumor development. A recent study (JNCI 2004, 96:1248-1254) found marginal evidence of an association between the presence of the mature MIC-1 protein nonsynonymous polymorphism H6D C-to-G (rs1058587) with reduced prostate cancer risk [odds ratio, 0.83; 95% confidence interval (95% CI), 0.69-0.99]. We tested this in a population-based study of 819 cases and 731 controls from Australia and found a similar, yet not significant, odds ratio of 0.85 (95% CI, 0.7-1.04; P = 0.11). We also tested the potential association between the H6D variant and disease-specific survival in 640 cases followed-up for an average of 8.2 years. We found that cases carrying the H6D G allele had an increased risk of death from prostate cancer than cases carrying two copies of the C allele (hazard ratio, 1.72; 95% CI, 1.06-2.78; P = 0.03). Our data suggest that the H6D variant in MIC-1 might play a role in prostate cancer, but it is difficult to explain how a variant can be associated with lower risk of developing prostate cancer but more aggressive growth if cancer develops. (Cancer Epidemiol Biomarkers Prev 2006;15(6):1223–5)

This article has been cited by other articles:

				I. Cheng, L. M. Krumroy, S. J. Plummer, G. Casey, and J. S. Witte MIC1 and IL1RN Genetic Variation and Advanced Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1309 - 1311. [Full Text] [PDF]

				K. S. Selander, D. A. Brown, G. B. Sequeiros, M. Hunter, R. Desmond, T. Parpala, J. Risteli, S. N. Breit, and A. Jukkola-Vuorinen Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 532 - 537. [Abstract] [Full Text] [PDF]